To describe patient characteristics, PTCL subtypes, and treatment patterns in US patients with PTCL treated 1L with A + CHP or CHOP outside of a clinical trial, we conducted the first study of real-world patient and treatment characteristics since FDA approval of BV in November 2018 for previously untreated sALCL or other CD30-expressing PTCLs in combination with CHP (ie, A + CHP). The gene discussed is TNFRSF8; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.